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Feline infectious peritonitis (FIP) is a fatal disease with no clinically effective treatment. 
This field study evaluated treatment with Polyprenyl Immunostimulant (PI) in cats with 
the non-effusive form of FIP. Because immune suppression is a major component in 
the pathology of FIP, we hypothesized that treatment with an immune system stimulant 
would increase survival times of cats with dry FIP. Sixty cats, diagnosed with dry FIP 
by primary care and specialist veterinarians and meeting the acceptance criteria, were 
treated with PI without intentional selection of less severe cases. The survival time from 
the start of PI treatment in cats diagnosed with dry FIP showed that of the 60 cats with 
dry FIP treated with PI, 8 survived over 200 days, and 4 of 60 survived over 300 days. 
A literature search identified 59 cats with non-effusive or dry FIP; no cat with only dry 
FIP lived longer than 200 days. Veterinarians of cats treated with PI that survived over 
30 days reported improvements in clinical signs and behavior. The survival times in our 
study were significantly longer in cats who were not treated with corticosteroids concur-
rently with PI. While not a cure, PI shows promise in the treatment of dry form FIP, but a 
controlled study will be needed to verify the benefit.
Keywords: feline infectious peritonitis, Polyprenyl immunostimulant, increased survival, chronic disease, feline 
coronavirus, field study
inTrODUcTiOn
Feline infectious peritonitis (FIP) is considered to be one of the most devastating diseases of domes-
tic cats with an incidence of 2–12% (1) in multi-cat environments. FIP has long been considered 
fatal (2–4) and a leading cause of mortality in young cats. No clinically effective treatments exist 
for FIP (5). FIP has an effusive form with abdominal and thoracic fluid accumulations; a median 
survival time of 9 days was noted in 21 cats with effusive FIP (6). Dry (non-effusive) FIP is often 
characterized by pyogranulomatous infiltrates in the liver, kidneys, lymph nodes, eyes, and central 
nervous system. The dry form of FIP has longer survival times within a range of 1–200  days 
noted in 59 cats (6–13). Two cats with mixed dry and wet forms FIP treated with combinations 
of corticosteroids, human alpha interferon, and nelfinavir survived 181 and 477 days (7).
Mutation of the enteric coronavirus that induces a tropism for macrophages initiates the disease 
process (3, 14). Cell-mediated immunosuppression due to a decrease in CD4+ lymphocytes is com-
monly seen in cats with FIP (14). Deficiencies in cell-mediated immunity promote an exuberant 
FigUre 1 | study decision-making tree at a glance.
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production of antibodies to the coronavirus, which results in 
deposition of immune complexes. With immunosuppression 
being a major component of pathophysiology, treatment with an 
immune stimulant is a rational approach.
Polyprenyl Immunostimulant (PI) is a veterinary biologic 
licensed by the U. S. Department of Agriculture for the reduction 
of the severity of signs of feline herpesvirus and is safe in cats 
over 8 weeks of age. It was used in our pilot study to treat cats 
with the dry form of FIP and produced promising results (15). 
It upregulates Th-1 type pathway via toll-like receptors (16) and 
may thus be of benefit in the diseases involving suppression of 
cellular immunity. In this field study, we tried to determine if 
PI treatment increases survival time and quality of life in cats 
diagnosed with dry FIP.
MaTerials anD MeThODs
general study Design
The field study had a single treatment arm, without a placebo 
control group, and was limited to cats with non-effusive or dry 
FIP. Only cats in the United States and Canada were accepted. 
Cats were diagnosed and treated by their primary care veterinar-
ians in conjunction with, in many cases, veterinary specialists. 
The veterinarians’ usual laboratories performed diagnostic tests. 
The study measured survival times from the start of PI treatment 
to death or euthanasia in terminal condition. The survival data 
from this study were compared to the historic data from a number 
of published articles. The study included cats of all signalments 
with clinical signs that represented the clinical spectrum of dry 
form FIP and were accepted and treated regardless of the sever-
ity of the disease or current treatments. Addition of appetite 
stimulants, antiemetics, antibiotics, vitamins, or special diets was 
not prohibited in our study, but the protocol advised against the 
use of corticosteroids because they cause immunosuppression. 
This study was carried out in accordance with the recommenda-
tions of the University of Tennessee Office of Laboratory Animal 
Care. The protocol was approved by the University of Tennessee 
Institutional Animal Care and Use Committee Protocol #1946.
case recruitment
Preliminary findings of a prior pilot study were published in 2009 
(15). The Veterinary Information Network site published a note 
of this trial in February 2010. Following the publication of the 
article and the note, practicing veterinarians with suspected or 
confirmed FIP cases contacted the Principal Investigator (AML) 
via e-mail or phone. All cats diagnosed with dry FIP by their 
veterinarian were considered and assigned a number (Figure 1). 
The initial diagnostics were done by veterinarians and reviewed 
and assessed for acceptance by AML based on sufficient data to 
support the diagnosis. In eight instances, AML accepted the cats 
TaBle 1 | Data collection form.
ID # Date Polyprenyl Immunostimulant (PI) shipped
Breed Multi cat? Origin
Age now Age at diagnosis
Type of feline infectious peritonitis Changes? Histopathology?
Date of Diagnosis Date of PI start Feline coronavirus (FCoV) titer Necropsy
Baseline Follow-up
Date 30 days 60 days 90 days 120 days 150 days 180 days 210 days
Weight
FCoV titer
Total protein
Globulins
Albumin
HCT
WBC
Neutrophils
Lymphocytes
ALT
Temperature
Uveitis
Neuro
Diarrhea
Abdominal mass
Steroids
Survival, days (check)
Date of death
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into the study without all laboratory diagnostics if the diagnosis 
was made by invasive techniques [immunohistochemistry (IHC), 
histopathology of biopsied material, or cytology of aspirates].
The initial veterinarian diagnosis was supported using the 
diagnostic approach proposed by Addie et al. (2) as reflected by 
our data collection form (Table  1), which included questions 
about patient age, history, environment, and observations such 
as pyrexia, weight loss, lethargy, anorexia, presence of abdominal 
lesions (masses, enlarged mesenteric lymph nodes). Required 
laboratory tests included complete blood count, biochemistry, 
and antibody titers to feline coronavirus (FCoV) and to pathogens 
that may mimic FIP. Surgical biopsy or aspiration of suspected 
lesions was encouraged. Necropsy was offered at the University 
of Tennessee free of charge or veterinarians could provide results 
of necropsy done by their providers.
The accepted cats received PI at 3 mg/kg orally three times per 
week and were clinically assessed by their veterinarians initially 
and then on follow-up examinations (monthly was recom-
mended), which collected the data for the analysis as shown in 
Table 2. Submission of the initial and follow-up laboratory test 
results was required. Refills of PI were shipped to collaborating 
veterinarians after the results of the follow-up evaluations were 
received. Monitoring of the progress of the cats accepted into the 
study was continued until death or euthanasia.
Veterinarians were advised to taper corticosteroid treatments 
if started before the study, but they were allowed to continue 
corticosteroid therapy at the lowest effective dose to maintain 
appetite and well-being.
Quality of life assessment was done using responses on the 
questionnaires and communications by the primary care vet-
erinarians and owners. In many cases, more extensive comments 
were recorded in the cat’s medical records, and all records were 
analyzed for the comments. We considered communications by 
veterinarians and owners regarding restoration of routines, activ-
ity levels, appetite improvement, etc. as indicators of the quality 
of life. Table 3 shows the questionnaire used to provide the data 
collected in the study.
statistical analysis of study results
Skewness and kurtosis statistics found non-normal distributions 
for all temporal variables associated with survival. Therefore, non-
parametric statistics were employed to yield inferences based on 
the respective research questions. Between-subjects comparisons 
for age groups and disease groups were conducted using Kruskal–
Wallis and Mann–Whitney U-tests. In addition to means and SD, 
medians and interquartile ranges were reported to give context 
to non-parametric statistical findings. Kaplan–Meier survival 
curves were used to display the cumulative survival of cats across 
TaBle 2 | Data analysis form.
Case #/Name
Breed
Male/female
Neutered
Age
Weight Did not start Polyprenyl Immunostimulant (PI) (check)
clinical signs 1 or 0
1 = yes
Diagnosis 1 or 0
0 = no
Ocular Abdominal imaging
Neuro Surgery
Decreased appetite Histopathology
Fever 102.5+ Cytology
Lethargy/depression Elevated globulins
Abdominal lesions Elevated total protein
Weight loss Decreased albumin
Feline coronavirus titer
Weight loss 1 or 0 compared to start 1:400
@ 30 days 1:800
@ 60 days 1:1,600+
@ 90 days Elevated WBC
@ 120 days Decreased HCT
@ 150 days Elevated neutrophils
Decreased neutrophils
Weight gain 1 or 0 compared to start Elevated lymphocytes
@ 30 days Decreased lymphocytes
@ 60 days Palpable/visible abdominal mass
@ 90 days Enlarged mesenteric lymph nodes
@ 120 days Colon involvement
@ 150 days
Weight, kg
@ 30 days
@ 60 days
@ 90 days
@ 120 days
@ 150 days
Status/survival Treatment
@ 30 days PI
@ 60 days Steroids at start of PI
@ 90 days Steroids at 1 month after start of PI
@ 120 days Steroids at 2 months after start of PI
@ 150 days Other
>150 days Other
Other
Lost to follow-up
Survived after PI start days
Improvement (subjective owner/vet assessment)
@ 30 days
@ 60 days
@ 90 days
@ 120 days
@ 150 days
>150 days
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TaBle 3 | Questionnaire for collection of patient information from the initial and follow-up examinations.
Physical exam findings
Date of exam Cat’s name
Owner’s name
Initial exam or recheck exam (mark)
Date of first dose of Polyprenyl Immunostimulant (PI)
Current dosing schedule
Please answer the following questions based on the current examination. If you check YES, give additional details including locations, duration, and severity as 
necessary
Comments
Weight loss Yes No Current weight:
Weakness Yes No
Appetite Yes No
Vomiting Yes No
Diarrhea Yes No
Fever Yes No
Lameness Yes No
Neurologic signs Yes No
Paraplegia Yes No
Ocular signs Yes No
Other Yes No
Initial history/history since last exam
Pi study
concomitant medications
Start date End date Drug Dosage Route
The questionnaires were submitted with results of laboratory tests.
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time. t-tests were employed for the comparison of mean and SD. 
An alpha value of 0.05 assumed statistical significance, and all 
analyses were conducted using SPSS Version 21 (Armonk, NY, 
USA: IBM Corp.).
resUlTs
consideration and acceptance
Consideration began March 1, 2010, and ended May 6, 2011. A 
total of 102 cats were considered for the study. All cats were diag-
nosed by their primary care veterinarians. There were 60 cats that 
met the qualification criteria and were therefore accepted into the 
study, and 23 of those had been referred to specialists, including 
veterinary ophthalmologists (12), internists (6), neurologists (3), 
ophthalmologist and a neurologist jointly (1), and a veterinary 
cardiologist (1). The remaining considered cats were disqualified 
before or during the study for the following reasons: insufficient 
diagnostic information (10), died before PI arrived (10), wet form 
FIP (10; PI was provided on a compassionate basis), treatment 
was stopped after one to two doses (2), overseas cases (2; PI was 
provided on a compassionate basis), incorrect diagnosis (2; PI 
was provided to one of the two cats on a compassionate basis), 
cats that were lost to follow-up because the veterinarian never 
provided any information after PI was shipped (5) and one cat 
enrolled in error, i.e., started the treatment prior to March 1, 2010 
(1). The accepted cats were evaluated and treated by veterinarians 
throughout the USA (58), and in Canada (2) in their practices. 
Fewer than 32% (19 of 60) of the cats were diagnosed at 10 days 
or less before the start of PI treatment. The remaining 41 cats were 
diagnosed with dry FIP 11 or more days before the beginning of 
treatment with PI. The mean time span between the diagnosis and 
the treatment was 22.97 ± 21.60 days. The cat that died after the 
administration of the first dose was diagnosed 161 days before the 
start of PI treatment.
Diagnostics
Signalment
There were 25 female, 1 hermaphrodite, and 34 male cats; 38 
were non-purebred and 22 were purebred (5 Ragdoll, 4 Siberian, 
3 Bengal, 3 Maine Coon, 2 Siamese, 2 Sphynx, 1 Tonkinese, 1 
Manx, and 1 Birman). Data on the household were provided for 
30 cats; 22 of the 30 were from multi-cat households and 8 from 
single-cat households. The age distribution of the 60 cats is shown 
in Figure 2. Seventy percent of the cats were under 24 months old, 
and 43% were under a year of age.
Clinical Signs
Fifty-nine of the 60 cats accepted into the study had clinical 
signs of FIP listed on the algorithm proposed by Addie et al. (2). 
The presence of clinical signs caused the cats’ owners to bring 
FigUre 3 | Diagnostic clinical signs in the cats accepted into the study at the time of the initial presentation. (a) Distribution of clinical signs in the study 
sample; (B) distribution of the number of clinical signs in individual cats.
FigUre 2 | age distribution of the qualified patients. The majority of cats 
diagnosed with dry feline infectious peritonitis were under 2 years of age (70%).
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the cat to their primary veterinarian for examination. During 
this initial examination, the clinical signs were documented in 
medical records. Figures 3A,B show the clinical signs and their 
distribution in the cats accepted into this study. Fifty-four of 59 
cats showed two or more clinical signs (Figure 3B) with five cats 
having one sign. Of the five cats with one sign, 2/5 were neuro-
logic, 1/5 ocular, 1/5 was evaluated because of persistent vomiting 
(an abdominal mass in the ileocolic region was discovered at the 
examination), and no data of a comprehensive initial examination 
were provided for one whose abdominal mass was discovered at 
physical examination.
One cat was included in the study that had no clinical signs 
when seen for neutering. This 8-month-old, male Siberian cat 
had a 10.7 g/dL serum total protein on a pre-anesthesia screen-
ing. The albumin was 2.1 g/dL, and the globulin was 8.6 with an 
A/G ratio of 0.24. The serum electrophoresis was interpreted as 
polyclonal gammopathy. The cat was anemic with a hematocrit of 
23%. The coronavirus antibody titer was positive at 1:1,600, and 
the feline leukemia antigen was negative and the feline immu-
nodeficiency antibody titer was negative. Thoracic radiographs 
showed an increase in cranial mediastinal density, and enlarged 
mesenteric lymph nodes were seen on abdominal ultrasound. 
Lymph node aspirates showed an increase in neutrophils on 
aspirate cytology.
Fifty-nine of the 60 cats on the study were categorized into 
one of five subforms of dry FIP based on the initial clinical signs, 
physical examination findings by primary veterinarians (and 
 specialists where applicable) and diagnostic workup. One cat 
had no clinical signs. The subform categories were distributed 
as follows: mixed (18/59), gastrointestinal (16/59), non-localized 
(11/59), ocular (9/59), neurologic (5/59).
At the initial presentation, the cats in the gastrointestinal 
category had anorexia (15/16), diarrhea (4), and/or vomiting 
(3), which were the primary reasons for the veterinary visit. 
Abdominal masses were found in 23/59 cats in the study, and 
the cats were categorized into either the gastrointestinal or mixed 
subform depending on whether they had additional clinical signs 
more often associated with another subform.
Ocular changes were reported in 17 cats and included anterior 
uveitis (17/17), retinal detachment (2/17), and keratic precipitates 
(4/17). One cat had a corneal ulcer. In 10/17 cats, ocular signs 
were the reason for the initial veterinary visit, and the cats were 
assigned to the ocular subform. The other 7 cats with ocular 
signs also had neurologic, abdominal, or non-localized signs 
and were classified as having mixed form. Neurologic signs, such 
as seizures, ataxia, and disorientation, were the main reason for 
the veterinary evaluation in 5/59 cats, and they were categorized 
TaBle 4 | hematology test results at the first presentation considered in the feline infectious peritonitis diagnosis.
Measurement reference interval Data sets received, n Mean Wnl, n (%) Below normal, n (%) above normal, n (%)
Albumin, g/dL 2.3–3.9 51 2.5 ± 0.5 32/51 (62.7) 19/51 (37.3) 0
Total protein, g/dL 5.9–8.5 51 9.8 ± 1.5 12/51 (23.5) 0 39/51 (76.5)
Globulins, g/dL 3.0–6.6 51 7.3 ± 1.6 18/51 (35.3) 0 33/51 (64.7)
A/G ratio 0.4–0.8 50a 0.37 ± 0.14 See the breakdown below:
<0.8 2/50 (4.0)b 48/50 (96.0) 0
<0.6 36/50 (72.0) N/A
<0.4 32/50 (64.0) N/A
Total bilirubin, mg/dL 0.0–0.4 50 0.5 ± 1.1 42/50 (84.0) N/A 8/50 (16.0)
WBC, 103/μL 4.2–15.6 51 15.6 ± 10.6 27/51 (52.9) 1/51 (2.0) 23/51 (45.1)
HCT, % 29–45 49 29.4 ± 6.9 20/49 (40.8) 28/49 (57.1) 1/49 (2.0)
Neutrophils Varies 44 N/A 19/44 (43.2) 1/44 (2.3) 24/44 (54.5)
Lymphocytes Varies 48 N/A 32/48 (66.7) 16/48 (33.3) 0
Seven animals were accepted based on the results of histopathology and cytology, and hematology results for two cats were received after the start of the treatment.
aIn one cat, concentrations of individual fractions were provided in lieu of the total globulin level and showed markedly elevated serum globulins and gammopathy. In another cat, no 
albumin levels were provided.
bA/G ratio was 0.8 in two cats; no cat had A/G ratio above 0.8.
WNL, within normal limits.
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as neurologic subform. The “non-localized” category (11/59) 
included cats with persistent fever uncontrollable-with-antibiot-
ics, lethargy, anorexia, and/or weight loss. The mixed subform 
cats had simultaneous signs from two or more subcategories, 
such as ocular combined with neurologic signs (e.g., uveitis and 
seizures).
Hematology, Serology, Differential Testing
Results of hematology tests from blood drawn during the initial 
examination are shown in Table 4. The blood testing data were 
unavailable for nine cats initially diagnosed based on histology 
and cytology findings consistent with FIP which were accepted 
as diagnostic. Two cats had serology and hematology tests done 
after the acceptance and the start of the treatment, and those 
later data are not included on the table. In some cases the test-
ing did not include items of interest, thus the data sets are not 
complete.
Jaundice was observed in one cat whereas hyperbiliru-
binemia was noted in 8/50 cats. Anemia (HCT <  29%) was 
observed in 28 of 49 cats. Increased WBC counts were noted 
in 20/50, neutrophilia was observed in 24/44, and lymphopenia 
in 16/48 cats.
Hyperglobulinemia and/or an albumin/globulin (A/G) ratio 
≤0.6 were noted in 48 of the 50 (96%) cats; two cats had A/G ratio 
equal to 0.8. The mean and SD of the value in the whole group was 
0.37 ± 0.14, and the spread is shown in Table 4.
The antibody titers were tested by IFA in 49 cats and, on the 
scale proposed by Addie et al. (17), were ranked from high posi-
tive (400–1,280; n = 13) to very high positive (>1,280, n = 36); 
10 of the 49 had titers > 12,800. In the two cats with low positive 
titers (100), the diagnosis was confirmed by immunostaining of 
biopsied lesions for the FCoV antigen. The 7b ELISA was used in 
three cats. The 3c PCR test done in three cats and showed negative 
results in two; these two cats were retested by IFA with positive 
results and also had the diagnosis by cytology.
We collected data sets on differential testing on 50 cats; the 
tests included FeLV antigen (45), feline immunodeficiency virus 
(FIV) (45), and toxoplasma (18). Except in one cat who was FIV 
positive, all other test results were negative. No serologic data 
were available for 10 cats. In the group with probable diagnosis 
with four missing data sets, one cat was diagnosed by neurologist 
based on the results of spinal tap and MRI, and another one had 
uveitis as a 3.3 lb 7-month Maine Coon kitten. In the group with 
the diagnosis confirmed by histologic, cytologic, and immuno-
chemical methods, of the six cats without differential data sets, 
four were diagnosed by IHC and two by histology on the biopsied 
tissues.
Specialized Laboratory Testing
Specialized laboratory testing methods used to confirm the dry 
FIP diagnosis are summarized in Table 5. Histology and cytology 
were performed in 36 cats and were conclusive in 34, they were 
further validated by immunostaining for FCoV antigen in 13/36 
cats. One cat with pyogranulomatous mesenteric lymphadenopa-
thy on lymph node aspirate also had elevated FCoV transcripts in 
the RT-PCR test on the same sample.
Three cats with neurologic disease had the diagnosis confirmed 
by CSF tap, and two of those had MRI results consistent with the 
FIP diagnosis. For one cat with ocular form ocular centesis fol-
lowed by quantitative PCR confirmed the presence of high titers 
of FCoV subgenomic mRNA of the M gene.
Necropsy was done of 15/60 cats. In 3/15, the necropsy was 
done of cats whose diagnosis was previously confirmed ante-
mortem by histology or cytology. Histopathological analysis of 
the necropsied tissues was conclusive for FIP for 14/15 cats and 
inconclusive for the 965-day survivor.
Concurrent Treatments Used in the Study
Of the 60 cats accepted into the field study, 13 received PI as the 
only treatment; the other 45 cats received treatments before the 
enrollment and/or concurrently with the PI including one or more 
of appetite stimulants, antiemetics, antibiotics, corticosteroids, 
vitamins, and/or special diets. There were no data on concurrent 
treatments for two cats.
TaBle 6 | survival time by the subform of the disease. no statistically 
significant differences were observed between any groups.
Form Treatment n survival, days 
mean ± sD
survival range, 
days
Ocular PI 3 99.33 ± 109.77 32–226
PI + ToCS 2 185.50 ± 159.10 73–298
PI + SyCS 4 67.75 ± 80.19 6–184
Neurologic PI + SyCS 5 38.80 ± 38.21 5–100
Gastrointestinal PI 11a 252.45 ± 533.25 15–1,829
PI + SyCS 5 53.20 ± 75.60 7–185
Non-localized PI 6b 268.83 ± 363.00 4–965
PI + ToCS 1c 60 60
PI + SyCS 4 11.00 ± 13.47 7–31
Mixed PI 8b 77.38 ± 94.87 1–131
PI + ToCS 6 32.67 ± 28.49 4–39
PI + SyCS 4 17.25 ± 16.46 6–77
No signs PI 1 148 148
PI, treated with Polyprenyl Immunostimulant, no concurrent corticosteroid treatment; 
PI + SyCS, treated with Polyprenyl Immunostimulant and systemic corticosteroids 
concurrently (includes 1 combined systemic and topical ocular corticosteroid 
treatment); PI + ToCS, treated with Polyprenyl Immunostimulant and topical ocular 
corticosteroids concurrently.
aIncludes two cats whose corticosteroid treatment was stopped at the start of PI treatment.
bEach number includes one cat whose corticosteroid treatment was stopped at the 
start of PI treatment.
cThe cat initially diagnosed with non-localized form started ocular topical corticosteroid 
treatment after uveitis developed.
TaBle 5 | specialized tests used in support of the diagnosis.
Test type Other tests on the 
same cat
Total tests, n Total histology, 
cytology, necropsy, n
Total csF 
tap, n
Total ocular 
centesis, n
Total 
imaging, n
By test Total
Cytology on fine needle aspirate 1a
}24 }36Histology
Only 8
+IHC 12
+Necropsy 2
+IHC+necropsy 1
Necropsy Only 12
CSF tap cytology
Only 1
}3+MRI 2
Q-PCR (m-gene mRNA) on aqueous humor 1 1
Thoracic and abdominal imaging 
(X-rays and ultrasound)
Only 3
}6+Histology or 
cytology or necropsy
3c
Consistent with FIP 34/36 3/3 1/1 3/3c
Inconclusive 1/25a 0 0 0
Inconsistent with FIP 1/25b 0 0 0
aLow cellularity.
bNecropsy results inconsistent with FIP; details are provided in the text.
cThe count is included into histology, cytology, necropsy total (n = 36).
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Sixty-two percent of the cats (36/60) were prescribed corticos-
teroids orally at the time of the initial diagnosis (27/36), topically 
(ocular, 7/36), or both (2/36). In 4/36 cats; the corticosteroid 
treatment was stopped before or shortly after beginning the treat-
ment with PI. Statistics on the use of corticosteroids are presented 
in Table  6. During the study, 31 cats received corticosteroids 
concurrently with PI (7 ocular topical and 25 systemic or systemic 
with ocular topical), and 27 cats were treated with PI without 
concurrent corticosteroids.
The four cats whose corticosteroid treatment was stopped in 
compliance with the requested test protocol before or at the start 
of PI treatment all had clinical signs consistent with FIP: weight 
loss (4/4), ataxia (1/4), abdominal masses (3/4), pyrexia (2/4), 
lethargy (2/4), anorexia (2/4) with the number of clinical signs 
from 2 to 5. Their laboratory tests also supported the diagnosis.
Two veterinarians started corticosteroid treatment when the 
cats deteriorated, one at 9 and at one 24 days before death; these 
cases were end-of-life care and were not counted as corticosteroid 
receivers. One cat was given one dose of nelfinavir the day before 
dying by her veterinarian owner.
Duration of Survival Post-Diagnosis and Clinical 
Progress
Duration of survival was determined as the time from the start 
of the PI treatment to death or euthanasia. Of the 60 cats treated 
with PI, 16 survived for over 100 days, 8 cats survived for over 
200 days, 4 cats survived for over 300 days (one additional cat sur-
vived for 298 days and is not counted here), 2 for over 900 days, 
and 1 cat for 1,829 days.
The survival times of the cats in the three groups, i.e., 
(1)  treated  with oral corticosteroids concurrently with PI, 
(2) treated with topical ocular corticosteroids concurrently with 
PI; and (3)  treated with PI without concurrent use of corticos-
teroids were significantly different from each other (p =  0.03, 
Kruskal–Wallis test). Table  7 lists all statistical data, and the 
FigUre 4 | survival curves for the cats receiving different treatments. (a) Survival of the cats treated with Polyprenyl Immunostimulant (PI) without concurrent 
corticosteroids (blue) was significantly longer (p = 0.003, Mann–Whitney U-test) than of the cats treated PI with corticosteroid administered concurrently by any 
route (red). (B) Survival of the cats treated with PI with concurrent corticosteroid administration topically (red) or orally (blue) did not differ significantly (p = 0.57, 
Mann–Whitney U-test).
TaBle 7 | survival of cats treated with or without corticosteroids concurrently with Polyprenyl immunostimulant by the method of the diagnosis.
Treatment n survival statistics, days p-value (Mann– 
Whitney U-test)
range Median Mean sD
all study cats (n = 60)
No concurrent corticosteroids 27 3–1,829 73.5 201.4 378.6 } 0.003Concurrent corticosteroids: 31 3–298 21.5 47.5 49.3
systemic 24 3–185 16 40.5 71.4 } 0.57topical 7 4–298 30 51.2 103.3
No data on concurrent treatments 2 1–15 N/A 8 9.9 N/A
Diagnosis confirmed by specialized tests on biopsied tissues (n = 34)
No concurrent corticosteroids 20 3–1,829 63 180.5 400.0 } 0.03Concurrent corticosteroids 12 4–185 20.5 38.9 51.3
No data on concurrent treatments 2 1–15 N/A 8 9.9 N/A
Diagnosed without confirmation on biopsied tissues (n = 26)
Necropsy/cytology inconclusive, no 
concurrent corticosteroids (n = 2)
7 4–965 148 261.1 329.7  
 
} 0.04No concurrent corticosteroids (n = 5)
Concurrent corticosteroids 19 3–298 22 52.8 74.2
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survival curves are presented in Figure 4. For cats who did not 
receive corticosteroids the median survival time was 73.5  days 
(n = 27). For the cats that received corticosteroids by any route 
concurrently with PI, the median survival time was 21.5  days 
(n =  31). The difference in survival times between the groups 
(corticosteroid receiver versus non-receiver) was significant 
(p =  0.003, Mann–Whitney U-test). There was no significant 
difference in the survival times of the cats treated with corti-
costeroids systemically or topically (p =  0.57, Mann–Whitney 
U-test). The four cats whose initial corticosteroid treatment was 
stopped before the treatment with PI survived for 79, 91, 279, and 
1,829 days. No data on concurrent treatments were available for 
two cats diagnosed by histology (1) and histology with IHC (1).
For the cats receiving PI alone and whose diagnosis was not 
confirmed by cytology, histology (ante- or post-mortem) survival 
times were 261.1 ±  329.7  days (4–965  days, median 148  days, 
n =  7); the cats who were treated with PI and corticosteroids 
concurrently with PI survived 52.8 ±  74.2  days (3–298  days, 
median 22 days, n = 19). The difference in the survival between 
the cats treated or untreated with corticosteroids concurrently 
with PI was significant (p = 0.03).
Cats whose diagnosis was confirmed by any type of analysis of 
biopsied or necropsied samples and treated with PI without con-
current corticosteroids survived 180.5 ± 400.0 days (3–1,829 days, 
median 63 days, n = 20); the cats treated with PI and corticoster-
oids concurrently survived 38.9 ± 51.3 days (4–185 days, median 
TaBle 8 | case summaries for the cats with feline infectious peritonitis (FiP) surviving over 300 days on Polyprenyl immunostimulant (Pi) treatment.
cat #2 (a) cat #52 (B) cat #78 (c) cat #105 (D)
Age at Dx 11 years 12 months 6 months 3 years
Sex FS FS MN MN
Breed DMH Bengal DSH DLH
Housing density 2 cats >3 cats >20 cats >3 cats
Household and FIP history Not known Previously lost 3 cats 
to FIP
Rescued by a rescue with FIP 
outbreak. Foster queen died of FIP
Not known
Keeping condition Inside Inside Inside Inside
Survival time, days 375 334 965 1,829
initial presentation and diagnostics
Days between initial visit 
and the start of PI
36 23 19 31
(Continued )
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20.5 days, n = 12). Two cats with inconclusive results of cytology 
(1) and necropsy (1) were accounted for as unconfirmed by those 
methods. The difference in the survival between the cats treated 
or untreated with corticosteroids concurrently with PI was 
significant (p =  0.04). A subgroup in which the diagnosis was 
also confirmed by IHC included eight cats treated with PI only 
(survived 8–1,829  days) and four cats treated with PI concur-
rently with corticosteroids (survived 7–185 days). No concurrent 
treatment data were available for one cat who survived one day. 
The size of those subgroups was insufficient to render statistical 
power to the analysis.
There was no significant difference in survival times between 
groups treated with PI only and diagnosed without biopsy-based 
tests (n =  20) versus those diagnosed with biopsy-based tests 
(n = 7; p = 0.27, Mann–Whitney U-test). Similarly, there was no 
difference in survival times between groups treated with corticos-
teroids concurrently with PI, which were diagnosed with tissue 
biopsies (n = 12) or without it (n = 19; p = 0.93 Mann–Whitney 
U-test).
No significant difference was found between the survival times 
for the cats receiving oral (n = 24) or topical ocular corticoster-
oids (n = 7, p = 0.57, Mann–Whitney U-test); and the median 
survival times were 16 and 30 days, respectively. No significant 
differences were noted between survival times of cats with dif-
ferent subforms of the disease regardless of the use of steroids 
(Table 6). Survival times of cats belonging to age groups under 6, 
7–12, 13–24 months, and over 25 months did not differ signifi-
cantly (p = 0.90, Kruskal–Wallis test).
After the beginning of treatment, the non-effusive form 
progressed to effusive in six cats (10%), and five of those died or 
were euthanized within 2 weeks thereafter. One cat (#31) whose 
initial corticosteroid treatment was stopped at the beginning of 
PI trial developed palpable abdominal masses and effusion after 
3 months of the treatment, which resolved by the next monthly 
visit. After 6 months on the treatment, a small mass was palpated 
and a small amount of fluid in mid-cranial abdomen was identi-
fied per the veterinarian’s records. The mass remained unchanged 
for the next two monthly visits, and the cat developed a distended 
belly with palpable fluid by the eighth month of the PI treatment. 
The amount of the fluid decreased by the next monthly check. 
Between 1 and 8 months on the treatment, the cat was doing clini-
cally well, gained weight, returned to normal routines, played, and 
had an appetite. The cat started declining in the ninth month of 
the PI treatment, lost weight, and there was an increased amount 
of abdominal fluid, and the cat died naturally after 279 days from 
the start of the treatment.
Three of the 17 cats with ocular disease survived for over 
180 days. Their initial signs included anterior uveitis (3), keratic 
precipitate (1), discoloration (1), anisocortia (1). In two of those 
cats the anterior uveitis was significantly improved or resolved 
after 2  months on PI treatment with no corticosteroids. The 
uveitis did not improve in the one cat who was receiving topical 
ocular corticosteroids concurrently with PI, and the eyes were 
enucleated.
In the 13/22 cats with palpable abdominal masses that sur-
vived over 30  days (life span 57–1,829  days), the reduction or 
resolution of the abdominal masses was noted in 6/13 during the 
first or second monthly follow-up examinations, three of the six 
cats received corticosteroids together with PI. One of the six cats 
(#31, described above), whose initial neurologic signs resolved 
and palpable masses were no longer reported after 1 month of 
the treatment, redeveloped a small palpable abdominal mass and 
abdominal fluid at 6  months into the treatment and 3  months 
prior to her natural death at 279 days; the corticosteroid treatment 
of this cat was stopped before PI treatment began. In another 
cat who received no corticosteroids, the masses were initially 
resected and did not reappear until 1 month prior to euthanasia 
at 374  days. The masses remained unchanged on palpation in 
4/13 cats; all four cats received no corticosteroid treatment. The 
findings were confirmed by ultrasound tests in one of those four, 
two cats died before the follow-up examination, and follow-up 
data were not available for one cat.
Four cats survived over 300 days and were considered long 
term survivors. Their records were scrutinized in considerable 
detail after death. The summary of the data for these cats is 
presented in Table 8 and Figure 5. All four cats were brought 
cat #2 (a) cat #52 (B) cat #78 (c) cat #105 (D)
Diagnostic signs Frequent vomiting, persistent 
diarrhea, weight loss. Not active. 
Palpable abdominal mass
Weight loss, vomiting, 
persistent diarrhea 
with occasional blood 
streak
URI, weight loss, weakness, 
possible diarrhea (too many cats to 
tell), poor appetite
Sudden weight loss, abdominal mass 
noted on ultrasound
Additional clinical signs CRF (Dx 1 month after FIP) None Submandibular lymphoadenopathy, 
gingivitis, conjunctivitis
Mild gingivitis at the end of life
Differential FIV-neg, FeLV-neg, 
toxoplasma-neg
FIV-neg, FeLV-neg, 
toxoplasma-neg
FIV-neg, FeLV-neg, toxoplasma-neg FIV-neg, FeLV-neg, toxoplasma-neg
Albumin, g/dL 2.3 2.6 2.6 2.3
Tp, g/dl 9.3 10.8 8.3 8.8
Globulin, g/dl 7.3 8.2 5.7 6.5
A/G ratio 0.3 0.3 0.5 0.4
Bilirubin, mg/dL 0.1 0.1 0.1 0.4
WBC cells/uL 23,400 22,600a 20,300 11,700
HCT, % 30.9 31.0a 8.4 33 (N 32–49)
Neutrophilia YES YESa YES NO
Lymphopenia YES YESa YES YES
Monocytosis YES NOa NO NO
Feline coronavirus (FCoV) 
titer
1:6,400 (ELISA IFA) 1:320 (7B ELISA) 1:1,600 (ELISA IFA) 1:800 (ELISA IFA)
FIP subtype GI GI Non-localized GI
Specialized laboratory 
testing and findings
Ultrasound, resection, and 
anastomosis of ileocecal region. 
Biopsies had pyogranulomatous 
reaction, IHC was FCoV 
antigen-positive
Not done Not done Polyclonal gammopathy, FIP mRNA-, 
ultrasound, FNA, biopsy. Histopathology 
revealed pyogranulomatous 
lymphoadenitis and pancreatitis. IHC 
positive for FCoV antigen
Concurrent medications Calcitrol 10 mg orally daily, 
Sucralfate PRN, Metoclopramide 
PRN
Metoclopramide PRN PI treatment stopped after about 
700 days
PI was tapered to 2× weekly after 
3 years and to once weekly after 4 years
Progress on the Pi treatment
Hyperglobulinemia and 
A/G ratio
No major change No major change Changed to WNL after 2 months Decreased to normal range after 1 month
Anemia No. Before death only No. Last test 40 days 
before death
Hematocrit increased to >30% 
after 2 months on PI. No data after 
700 days
Increased to >35% after 2 months on PI, 
decreased before death
Diagnostic clinical signs Resolved Resolved Resolved Resolved
Life quality Improved and returned to normal Returned to normal Improved, stable (records until the 
end of PI treatment). Cystitis Dx 
after 600 days on PI
Returned to normal
Cause of death Euth: weight loss, lethargic, 
dehydrated, trouble breathing
Euth: inappetance, 
lethargy, weight loss, 
fever
Euth in extremis Euth: anorexia, vomiting, severe 
azotemia indicating kidney failure or 
severe trauma from infection or toxin/
ischemic injury. No abdominal mass on 
ultrasound before death
Necropsy Pleural effusion, small mesenteric 
mass, close to the resection site. 
Multifocal granulomatous colitis 
and hepatitis consistent with FIP
Not done Mild changes consistent with prior 
hepatic injury and nephritis, cystitis 
cystica
Not done
aTested 9 days after the start of the PI treatment.
CRF, chronic renal failure, chronic renal insufficiency; Euth, euthanasia; FCoV, feline corona virus; FeLV, feline leukemia virus; FIV, feline immunodeficiency virus; FNA, fine needle 
aspirate; IHC, immunohistochemistry; URI, upper respiratory infection; WNL, within normal limits.
TaBle 8 | continued
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FigUre 5 | Dynamics of hcT, a/g ratio, and weight in the four longest survivors on the study. (a) Cat #2, 375 days survival; (B) Cat # 52, 334 days 
survival; (c) Cat #78, 965 days survival; (D) Cat #105, 1,829 days survival.
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initially to their veterinarians with signs typical of dry FIP, 
including inappetance (3/4), lethargy (3/4), and weight loss 
(4/4). One cat had persistent diarrhea and vomiting; in two of the 
four cats, abdominal masses were detected by their veterinarians. 
The A/G ratios for all four cats ranged from 0.3 to 0.5. Three of 
the four cats were anemic, and all had moderate to high coro-
navirus antibody titers of 1:320 (K-ELISA), 1:800, 1:1,600 and 
1:6,400 (all three by IFA). In two of the four cats, histopathology 
of biopsied tissues had pyogranulomatous inflammation, and the 
diagnosis was validated by immunostaining for FCoV antigen. 
Cat 105, the longest survivor (1,829  days), initially received 
prednisolone to control the weight loss but the corticosteroid 
therapy was discontinued at the start of PI treatment. Based on 
reports by owners and veterinarians, all four cats returned to 
normal behavior by the first checkup visit, about 1 month from 
the beginning of the treatment, and the weight either stabilized 
or increased. The clinical signs of vomiting, diarrhea, lethargy, 
etc. also resolved. Three cats lost weight before death; data were 
unavailable for one. The A/G ratios increased after 2 months on 
the PI treatment in the two longest survivors, and reached >0.8, 
and anemia improved in one and resolved in another one. The 
borderline anemia, although somewhat improved, was present 
in the Cats 2 and 52 survivors and became more pronounced 
before death. The treatment was stopped after about 700 days in 
Cat 78, and no laboratory test data are available from that time 
until his death at 965 days when necropsy was performed. The PI 
treatment frequency was tapered first to twice weekly and then 
to once weekly in Cat 105. All cats were euthanized in extremis. 
The necropsies on the Cat 2 showed lesions consistent with FIP. 
The necropsy on Cat 78 showed lymphoplasmacytic interstitial 
nephritis and cystitis cystica without lesions of FIP. Toxicosis, 
azotemia, and ischemia probably associated with renal failure led 
to the euthanasia of Cat 105. The ultrasound showed no masses 
on the internal organs and the results were unremarkable; no 
necropsy was performed.
A number of veterinarians and owners voluntarily provided 
information on the quality of life in communications, and vet-
erinarians commented from the first recheck on after 30 days of 
PI treatment using the questionnaire. More quality-of-life-related 
comments were recorded by veterinarians on medical records 
which were analyzed. We found improved quality-of-life com-
ments for 32 of the 34 cats that survived for more than 30 days. 
All comments for those 32 cats indicated an improvement in 
the perceived quality of life (“return to normal,” “as before the 
disease,” “appears healthy,” got back to normal routines, and/or 
improvement in appetite, mobility, socialization, and responsive-
ness) during the preceding period, most commonly every month 
on the treatment. Weight stabilized or increased in 31/32 patients, 
while 1/32 continued to lose weight while showing improvement 
in behavior and appetite.
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No toxicity or adverse events due to the administration of PI 
were reported by the veterinarians or owners.
DiscUssiOn
We report that of the 60 cats with presumed non-effusive FIP 
diagnosed using the recognized algorithm (2) and treated with 
PI 1 cat survived for 1,829 days, 2 cats for over 900 days, 4 cats 
survived over 300 days, 8 for over 200 days (one of those survived 
298  days), and 16 lived over 100  days from the start of treat-
ment. The 31 cats given oral corticosteroids or receiving topical 
ocular corticosteroids concurrently with PI survived a mean of 
47. 5 ± 49.3 days (3–298 days, median 21.5 days), while the 27 
cats treated with PI without corticosteroids survived a mean of 
201.4 ± 378.6 days (3–1,829 days, median 73.5 days), which is 
significantly longer (Table  7; Figure  4A). Currently the most 
common therapy for FIP is corticosteroid (2, 4).
Of the 35 cats started on corticosteroids at the time of diagnosis, 
the treatment was stopped in 4 cats before the start on PI, while 
31 were continued on corticosteroids concurrently with PI. The 
four cats whose corticosteroid treatment was stopped survived a 
mean of 569.50 ± 844.65 days (79–1,829 days, median 91 days). 
These four cats had multiple signs of the disease, and none of the 
four cats at the time of diagnosis appeared less severely affected 
than the other cats in our study.
In the subgroups of FIP, there was a difference in the likelihood 
of corticosteroid use, with 31% (5/16) in the GI subform of FIP 
receiving corticosteroids to 100% (5/5) in neurologic subforms 
receiving corticosteroids. Both topical and ocular corticosteroids 
appeared to reduce survival times when given concurrently with 
PI (Figure 4B).
We accepted all cats that met the inclusion criteria and did not 
intentionally select less severe cases for the study. No assessment 
of the severity of the disease was done. Our first assumption was 
that corticosteroids were used in the more severe cases but we 
could find no justification for that assumption. But the small 
sample size does not allow ruling out that the shorter survival 
times of the cats concurrently treated with PI and corticosteroids 
may indirectly reflect the severity of the disease.
We observed no statistically significant differences between 
survival of the cats either for the subforms of the disease (ocular, 
neurologic, gastrointestinal, non-localized, or mixed), or between 
different age groups (≤6 months, 7–12 month, 13–24 months, and 
over 25 months) which may be because of a very wide variance in 
each of the groups. We did not have a sufficient number of cats in 
each group for the statistical power to validate any conclusions.
The literature offers limited data on survival times of cats with 
dry form FIP with or without treatments. Cats in the literature 
with dry form FIP treated with corticosteroids and supportive 
care had a survival range of 1–200  days (n =  51). One early 
study (8) examined field records for intestinal, granulomatous 
manifestation (n =  26), and reported the survival time in this 
non-effusive FIP form as “up to 9 months” in a cat that was lost to 
follow-up. More careful retrospective record studies reported the 
survival time at 7–45 days in cats with histologically confirmed 
diagnosis (8 effusive, 5 non-effusive, no separate data provided; 
9), and 7–60 days (n = 4, 1 of 4 was on IFNα-rHU; 10). Reports 
of clinical studies in natural infection put survival with dry FIP 
at 38 days (n = 1; 11), 1–171 days (n = 11; 6), 6–33 days without 
treatment (n = 4), and 4–42 days in cats previously given an FIP 
vaccine as a preventative (n = 4; 13).
The literature mentions an individual cat diagnosed with 
the dry form that survived for 200  days with glucocorticoid 
and ω-interferon treatment (6) and two cats survived 181 and 
477 days with mixed dry/wet form treated with glucocorticoid, 
human α-interferon, and nelfinavir (7). A recent mention (18) 
of a natural survival time of over a year without treatment in 
cats with dry form FIP referred to cats that were treated with 
PI (15).
The survival times from this study were compared to published 
data of cats with dry form FIP. The data suggest a lengthening 
of the survival times in cats treated with PI. The survival times 
equaled or exceeded the longest survival times reported in the 
literature for dry FIP, with 8 of 60 cats in our study exceeding the 
maximum reported number of 200 days.
The diagnosis of dry FIP in our field study was done at differ-
ent levels of diagnostic certainty, and we compared survival times 
in the subgroups—diagnosed, or not, by histologic, cytologic, or 
immunostaining tests and found no statistically significant dif-
ferences based on the proof of the diagnosis, although there were 
significant differences between cats treated with corticosteroids 
concurrently with PI or not. There was no significant difference in 
the survival times of cats who did not receive steroids regardless 
of whether they were diagnosed by any biopsy-based method or 
diagnosed without invasive methods. The survival time was the 
same regardless of the diagnostic method used.
A comparison of mean and SD values for the survival times 
of cats with dry FIP showed that the survival time of cats in 
our study was significantly longer for the group treated with PI 
without concurrent corticosteroid treatment (201.4 ± 378.6 days, 
n = 27) than the published 38.4 ± 48.8 days (n = 11; 7); p = 0.04. 
The survival time for the group treated with corticosteroids con-
currently with PI was 47.45 ± 49.26 days (n = 31), which does 
not significantly differ (p = 0.59) from the published value (7). 
Corticosteroids are the usual treatment for FIP signs; however, 
they need to be used with caution if PI is used.
Feline infectious peritonitis is considered 100% fatal which, 
in our study plan, precluded for ethical reasons an experimental 
design that used an untreated placebo group. For statistical com-
parison of data, a placebo group is ideal. This study was modeled 
on human studies that use single-arm trials of anti-cancer drugs 
with survival as the end-point. In those studies, no placebo or best 
accepted therapy is used because of the lack of known beneficial 
treatment and the universally grave prognosis (19). Our study was 
a field trial dependent on primary care veterinarians to identify 
candidates for the study and treat those accepted in accordance 
with the protocol. On ethical grounds and considering the reluc-
tance of cat owners to participate in a placebo-controlled study, 
we elected the presented study design.
Our decision to exclude cats with wet form FIP was based on 
the rapid progression of the wet form (median of 9 days; 5) which 
we assumed correctly to be faster than the expected median time 
needed for acceptance of a cat into the study (which turned out 
to be 22.97 ± 21.60 days). Additionally, our prior limited studies 
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of PI in effusive FIP did not appear promising while treatment of 
dry form FIP was encouraging.
The diagnosis of dry FIP was done at three levels of certainty: 
(1) highly probable, diagnosis supported by history, clinical 
signs, and laboratory findings without specialized lab tests; 
this category included neurologic forms in which biopsies are 
not possible and ocular forms when ocular centesis was used; 
(2) with histologic or cytologic confirmation of the diagnosis 
with or without immunostaining; this group also included cats 
with confirmation done on necropsied tissues; and its subgroup 
(3) with the confirmation of the presence of the FCoV antigen 
by IHC. There was no statistically significant difference in the 
survival between the cats diagnosed at different certainty levels 
and treated with PI only. We could not compare survival times 
between the subgroups treated with corticosteroids due to insuf-
ficient sample power.
Making an antemortem diagnosis of dry FIP is notoriously 
hard in the absence of a single, standardized test and relies on 
the combination of non-specific “disease-indicators” especially if 
the owners do not allow invasive procedures. Test data in clinical 
chemistry, hematology, serology, clinical assessment, histology, 
etc. have different predictive values and are not pathognomonic 
(2, 14, 18, 20). In the absence of a single, 100% reliable diagnostic 
approach, all diagnostic efforts are aimed to increase the “index 
of suspicion” as it was called by Diaz and Poma (21). The require-
ments for a “gold standard” vary between research groups with 
some accepting histopathology and others stressing IHC (14, 20), 
while the consensus document by Addie et al. (2) avoids the defi-
nition of the “definitive diagnosis” altogether. In clinical practice, 
most diagnoses are made by laboratory findings consistent with 
FIP and excluding other diseases (3, 18).
The primary care veterinarians and veterinary specialists 
treating these cats were comfortable with the diagnosis of dry 
form FIP, but we are using the term “presumptive FIP” because 
the “gold standard” of coronavirus antigen by IHC in lesions 
consistent with dry form FIP was not achieved with all cats. The 
cats in this study were diagnosed by their veterinarians based on 
the assessment of the combination of signalment, clinical signs, 
and as many tests as necessary to rule out other diseases and 
support the diagnosis, relying on experience (18), in the mode 
documented by Rohrbach et  al. (22). The diagnosis, made by 
the primary care veterinarian in conjunction with specialists as 
needed, was reviewed by AML using criteria consistent with the 
evidence-based algorithm (2). Specialized testing such as histol-
ogy, cytology, CSF tap, PCR on aqueous humor, IHC, and nec-
ropsy was done in 36/60 cats. When the presumptive diagnosis is 
made, owners are often reluctant to get the confirmation through 
the invasive procedures.
The diagnosis for each cat on the study was established indi-
vidually, and we also compared our data to the data published for 
cats with a confirmed diagnosis of FIP (1, 7, 20, 23). Signalment 
and housing density were similar to the reported data (23) with 
the majority of the cats being young, non-pedigreed, and origi-
nating from multi-cat households. The age distribution of the FIP 
patients in our study underscored a well-established age bias for 
FIP (12, 22). Clinical presentations observed in our sample were 
similar to the reported for the cats with dry form FIP (20, 23).
Diseases that may be clinically similar to FIP were excluded by 
specific tests in most cats. Feline leukemia virus (FeLV) antigen 
and FIV antibody were measured in 50/60 cats and one of those 
was positive for FIV antibodies. The FIP diagnosis of the only 
FIV-positive cat was given by a neurologist based on the results 
of MRI and CSF tap. Antibodies for toxoplasma were measured 
in 18 cats and all were negative. Ten cats were not tested for FeLV 
and FIV; six had the diagnosis confirmed by specialized tests 
on the biopsied tissues (four IHC and two histology), and the 
other four had a number of strong FIP indicators and considered 
presumptive.
We analyzed the initial biochemical parameters of diagnostic 
value for FIP. In young cats, with high serum globulin and low A/G 
ratios, there are few conditions except FIP that are likely. Plasma 
cell and B-lymphocyte malignancies can produce a monoclonal 
gammopathy, but these conditions are rare in young cats. Chronic 
inflammatory or infectious conditions such as chronic abscesses 
and pyothorax could increase serum globulin levels but these 
conditions would likely be identified by diagnostic evaluation. 
Hyperglobulinemia and/or an albumin/globulin (A/G) ratio ≤0.6 
were noted in 48 of the 50 (96%) cats; two cats had A/G ratio equal 
0.8. At the initial evaluation of the cats in our study, there was 
hyperglobulinemia in 64.7% of the cats, which is similar to the 
value reported in the literature in the combined wet-dry group 
(7). The albumin/globulin ratio offers the highest positive predic-
tion value for FIP (20). In our group it was 0.37 ± 0.14, which is 
consistent with the reported values for FIP in general (20) and 
lower than the mean and SD reported for the initial presentation 
by Tsai et al. (7).
Hyperbilirubinemia occurred in 16% of the cats which is 
consistent with dry form FIP and is lower than reported in the 
groups with wet FIP (7, 23). Hyperglobulinemia is an important 
diagnostic sign because it is rarely associated with diseases 
other than FIP in young kittens, which is the most often affected 
group.
The initial hematologic parameters of diagnostic value for FIP 
were analyzed. Leukocytosis and neutrophilia were found in 45.1 
and 54.5% of the cats, respectively; both values are consistent 
with the published (23). Lymphopenia was present in 33.3% of 
the study cats consistent with previous studies (23).
Coronavirus antibody titers are somewhat helpful in the 
diagnosis of FIP (2, 4, 17). Negative serum antibody titers make 
the diagnosis of FIP unlikely, while high and very high titers 
are supportive of the diagnosis. However, mid-range to high 
antibody titers can occur with coronavirus infection without FIP. 
All tested cats accepted to the study had coronavirus antibody 
titers with most of the cats having high (400–1,280; n = 13), very 
high (>1,280, n = 36), or extremely high positive titers (>12,800, 
n = 10).
The only cat on the study without signs of FIP was diagnosed 
by the veterinarian after a pre-neuter checkup. The follow-up 
cytology of the mesenteric lymph node aspirate was inconclusive 
because the cellularity was insufficient to definitively demon-
strate pyogranulomatous inflammation, although there was no 
evidence of neoplasia or other infectious organisms. The cat 
developed effusion and died after 148 days of the treatment with 
PI and corticosteroids concurrently.
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